Journal
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA
Volume 17, Issue 3, Pages 485-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.soc.2008.02.007
Keywords
-
Ask authors/readers for more resources
Tremendous progress has been made in surgery for cancer of the esophagus and gastroesophageal junction. After primary surgery, overall 5-year survival rates of 35% or more are obtained in high-volume units, and for advanced stage III cancer, 5-year survival reaches 25%. Multimodality therapy, in particular induction chemotherapy with or without radiotherapy, results in a complete response rate in up to 25% of the patients. Approximately 50% of the patients receiving such treatment do not respond, however, and their outcome is dismal. Therefore, further efforts are needed to elaborate more precise algorithms for selecting candidates for induction therapy versus primary surgery.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available